Capricor Therapeutics, Inc.CAPRNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank59
3Y CAGR+1.0%
5Y CAGR+25.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+1.0%/yr
Quarterly compound
5Y CAGR
+25.3%/yr
Recent deceleration
Percentile
P59
Within normal range
vs 5Y Ago
3.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.62% |
| Q3 2025 | -7.66% |
| Q2 2025 | 16.56% |
| Q1 2025 | 29.96% |
| Q4 2024 | 23.26% |
| Q3 2024 | -5.57% |
| Q2 2024 | 12.65% |
| Q1 2024 | 11.68% |
| Q4 2023 | -0.89% |
| Q3 2023 | 13.74% |
| Q2 2023 | 15.09% |
| Q1 2023 | 22.94% |
| Q4 2022 | 13.22% |
| Q3 2022 | 10.86% |
| Q2 2022 | -2.94% |
| Q1 2022 | 19.99% |
| Q4 2021 | 69.60% |
| Q3 2021 | -28.12% |
| Q2 2021 | 6.10% |
| Q1 2021 | 20.08% |
| Q4 2020 | 4.41% |
| Q3 2020 | 36.41% |
| Q2 2020 | 66.86% |
| Q1 2020 | 39.39% |
| Q4 2019 | -3.38% |
| Q3 2019 | -47.82% |
| Q2 2019 | -9.22% |
| Q1 2019 | -36.43% |
| Q4 2018 | -9.04% |
| Q3 2018 | -7.58% |
| Q2 2018 | 25.66% |
| Q1 2018 | 7.11% |
| Q4 2017 | 35.23% |
| Q3 2017 | -40.47% |
| Q2 2017 | -3.96% |
| Q1 2017 | 22.17% |
| Q4 2016 | -43.60% |
| Q3 2016 | 9.73% |
| Q2 2016 | -0.76% |
| Q1 2016 | 30.32% |